The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
Coronary artery calcification: entry to new frontier of PCSK9 inhibitors Today, rapid aging in society is making progress in developed countries. One of the most serious health problems in an aging society is atherosclerosis, of which final phase is coronary artery calcification (CAC). CAC could inc...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2018
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/1ffab4119ea846228305fe184e1e8207 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:1ffab4119ea846228305fe184e1e8207 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:1ffab4119ea846228305fe184e1e82072021-12-02T16:05:43ZThe annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy10.1038/s41514-018-0026-22056-3973https://doaj.org/article/1ffab4119ea846228305fe184e1e82072018-06-01T00:00:00Zhttps://doi.org/10.1038/s41514-018-0026-2https://doaj.org/toc/2056-3973Coronary artery calcification: entry to new frontier of PCSK9 inhibitors Today, rapid aging in society is making progress in developed countries. One of the most serious health problems in an aging society is atherosclerosis, of which final phase is coronary artery calcification (CAC). CAC could increase the risk of complications during coronary catheterization and coronary artery bypass surgery as well as ischemic heart disease (IHD). We, members in the aging society, would see much more patients with CAC in the near future. We, however, have no medications for CAC today. Moreover, statins that are used in the world have been known for CAC formation after long-term use. The team led by Yuichi Ikegami and Ikuo Inoue in Japan’s Saitama Medical University found that CAC in patients with atherosclerosis is improved by PCSK9 inhibitors compared to statins by using coronary computed tomographic angiography. This study shows us a hint that could lead us to new preventive therapies of IHD.Yuichi IkegamiIkuo InoueKaiji InoueYuichi ShinodaShinichiro IidaSeiichi GotoTakanari NakanoAkira ShimadaMistuhiko NodaNature PortfolioarticleGeriatricsRC952-954.6ENnpj Aging and Mechanisms of Disease, Vol 4, Iss 1, Pp 1-8 (2018) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Geriatrics RC952-954.6 |
| spellingShingle |
Geriatrics RC952-954.6 Yuichi Ikegami Ikuo Inoue Kaiji Inoue Yuichi Shinoda Shinichiro Iida Seiichi Goto Takanari Nakano Akira Shimada Mistuhiko Noda The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy |
| description |
Coronary artery calcification: entry to new frontier of PCSK9 inhibitors Today, rapid aging in society is making progress in developed countries. One of the most serious health problems in an aging society is atherosclerosis, of which final phase is coronary artery calcification (CAC). CAC could increase the risk of complications during coronary catheterization and coronary artery bypass surgery as well as ischemic heart disease (IHD). We, members in the aging society, would see much more patients with CAC in the near future. We, however, have no medications for CAC today. Moreover, statins that are used in the world have been known for CAC formation after long-term use. The team led by Yuichi Ikegami and Ikuo Inoue in Japan’s Saitama Medical University found that CAC in patients with atherosclerosis is improved by PCSK9 inhibitors compared to statins by using coronary computed tomographic angiography. This study shows us a hint that could lead us to new preventive therapies of IHD. |
| format |
article |
| author |
Yuichi Ikegami Ikuo Inoue Kaiji Inoue Yuichi Shinoda Shinichiro Iida Seiichi Goto Takanari Nakano Akira Shimada Mistuhiko Noda |
| author_facet |
Yuichi Ikegami Ikuo Inoue Kaiji Inoue Yuichi Shinoda Shinichiro Iida Seiichi Goto Takanari Nakano Akira Shimada Mistuhiko Noda |
| author_sort |
Yuichi Ikegami |
| title |
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy |
| title_short |
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy |
| title_full |
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy |
| title_fullStr |
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy |
| title_full_unstemmed |
The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy |
| title_sort |
annual rate of coronary artery calcification with combination therapy with a pcsk9 inhibitor and a statin is lower than that with statin monotherapy |
| publisher |
Nature Portfolio |
| publishDate |
2018 |
| url |
https://doaj.org/article/1ffab4119ea846228305fe184e1e8207 |
| work_keys_str_mv |
AT yuichiikegami theannualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT ikuoinoue theannualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT kaijiinoue theannualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT yuichishinoda theannualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT shinichiroiida theannualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT seiichigoto theannualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT takanarinakano theannualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT akirashimada theannualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT mistuhikonoda theannualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT yuichiikegami annualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT ikuoinoue annualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT kaijiinoue annualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT yuichishinoda annualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT shinichiroiida annualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT seiichigoto annualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT takanarinakano annualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT akirashimada annualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy AT mistuhikonoda annualrateofcoronaryarterycalcificationwithcombinationtherapywithapcsk9inhibitorandastatinislowerthanthatwithstatinmonotherapy |
| _version_ |
1718385134233714688 |